BlackRock’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-13,536,964
| Closed | -$545M | – | 5705 |
|
|
2026
Q1 | $545M | Buy |
13,536,964
+7,276,851
| +116% | +$157M | 0.01% | 1043 |
|
|
2025
Q4 | $157M | Sell |
6,260,113
-8,352
| -0.1% | -$196K | ﹤0.01% | 1839 |
|
|
2025
Q3 | $142M | Sell |
6,268,465
-136,534
| -2% | -$3.18M | ﹤0.01% | 1875 |
|
|
2025
Q2 | $111M | Buy |
6,404,999
+75,401
| +1% | +$1.4M | ﹤0.01% | 1973 |
|
|
2025
Q1 | $138M | Sell |
6,329,598
-148,391
| -2% | -$4.1M | ﹤0.01% | 1802 |
|
|
2024
Q4 | $207M | Buy |
6,477,989
+285,621
| +5% | +$8.59M | ﹤0.01% | 1658 |
|
|
2024
Q3 | $179M | Buy |
6,192,368
+397,096
| +7% | +$14.7M | ﹤0.01% | 1726 |
|
|
2024
Q2 | $222M | Buy |
5,795,272
+300,681
| +5% | +$13.6M | 0.01% | 1543 |
|
|
2024
Q1 | $323M | Buy |
5,494,591
+113,338
| +2% | +$7.22M | 0.01% | 1316 |
|
|
2023
Q4 | $322M | Buy |
5,381,253
+108,507
| +2% | +$5.5M | 0.01% | 1328 |
|
|
2023
Q3 | $201M | Sell |
5,272,746
-474,881
| -8% | -$20.9M | 0.01% | 1550 |
|
|
2023
Q2 | $524M | Sell |
5,747,627
-1,907,824
| -25% | -$165M | 0.01% | 910 |
|
|
2023
Q1 | $505M | Sell |
7,655,451
-48,743
| -0.6% | -$2.81M | 0.01% | 912 |
|
|
2022
Q4 | $398M | Buy |
7,704,194
+617,864
| +9% | +$32.8M | 0.01% | 1039 |
|
|
2022
Q3 | $484M | Buy |
7,086,330
+287,786
| +4% | +$17M | 0.02% | 845 |
|
|
2022
Q2 | $307M | Buy |
6,798,544
+874,624
| +15% | +$39.9M | 0.01% | 1211 |
|
|
2022
Q1 | $301M | Buy |
5,923,920
+58,208
| +1% | +$2.57M | 0.01% | 1354 |
|
|
2021
Q4 | $277M | Buy |
5,865,712
+399,521
| +7% | +$15.7M | 0.01% | 1499 |
|
|
2021
Q3 | $180M | Sell |
5,466,191
-204,541
| -4% | -$11.5M | 0.01% | 1797 |
|
|
2021
Q2 | $358M | Sell |
5,670,732
-216,216
| -4% | -$11.2M | 0.01% | 1320 |
|
|
2021
Q1 | $253M | Sell |
5,886,948
-128,000
| -2% | -$6.06M | 0.01% | 1564 |
|
|
2020
Q4 | $344M | Buy |
6,014,948
+34,687
| +0.6% | +$1.47M | 0.01% | 1189 |
|
|
2020
Q3 | $180M | Sell |
5,980,261
-196,547
| -3% | -$5.87M | 0.01% | 1463 |
|
|
2020
Q2 | $202M | Buy |
6,176,808
+360,548
| +6% | +$11.6M | 0.01% | 1358 |
|
|
2020
Q1 | $156M | Buy |
5,816,260
+1,058,755
| +22% | +$37.6M | 0.01% | 1343 |
|
|
2019
Q4 | $146M | Buy |
4,757,505
+55,135
| +1% | +$1.53M | 0.01% | 1728 |
|
|
2019
Q3 | $113M | Buy |
4,702,370
+200,253
| +4% | +$5.51M | ﹤0.01% | 1822 |
|
|
2019
Q2 | $114M | Buy |
4,502,117
+781,085
| +21% | +$15.9M | ﹤0.01% | 1816 |
|
|
2019
Q1 | $72.6M | Sell |
3,721,032
-9,594
| -0.3% | -$151K | ﹤0.01% | 2074 |
|
|
2018
Q4 | $49.2M | Buy |
3,730,626
+877,431
| +31% | +$13.5M | ﹤0.01% | 2254 |
|
|
2018
Q3 | $50.7M | Buy |
2,853,195
+54,227
| +2% | +$1M | ﹤0.01% | 2365 |
|
|
2018
Q2 | $61.6M | Buy |
2,798,968
+1,692,121
| +153% | +$38.9M | ﹤0.01% | 2249 |
|
|
2018
Q1 | $24.5M | Buy |
1,106,847
+134,695
| +14% | +$2.65M | ﹤0.01% | 2653 |
|
|
2017
Q4 | $21.1M | Buy |
+972,152
| New | +$14.3M | ﹤0.01% | 2754 |
|
Other funds holding APLS
BlackRock's APLS Position: Q2 2026 in Review
BlackRock sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 13,536,964 shares — an estimated $545M sold.
BlackRock first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $545M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- BlackRock reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 13,536,964 Apellis Pharmaceuticals shares in Q2 2026, an estimated $545M.
- BlackRock first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- BlackRock's Apellis Pharmaceuticals position peaked at $545M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.